February 1, 2017
Daiichi Sankyo is expecting high odds of success for the development of a chimeric antigen receptor T (CAR-T) therapy, KTE-C19, a candidate for non-Hodgkin’s lymphoma recently licensed from US biotech Kite Pharma, Executive Vice President Kazunori Hirokawa said on January...read more